MedTrace Logo

Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)

NCT00424710 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2014-11-05

No results posted yet for this study

Summary

This is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal choroidal vasculopathy as diagnosed by fluoresceins/indocyanine green (FA/ICG) angiography.

Conditions

  • Polypoidal Choroidal Vasculopathy

Interventions

DRUG

ranibizumab intravitreal injection

liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Hawaii Pacific Health

    lead OTHER

Principal Investigators

  • Gregg T Kokame, MD · The Retina Center at Pali Momi

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00424710 on ClinicalTrials.gov